Literature DB >> 10073967

Binding of beta-VLDL to heparan sulfate proteoglycans requires lipoprotein lipase, whereas ApoE only modulates binding affinity.

F de Beer1, W L Hendriks, L C van Vark, S W Kamerling, K W van Dijk, M H Hofker, A H Smelt, L M Havekes.   

Abstract

The binding of beta-VLDL to heparan sulfate proteoglycans (HSPG) has been reported to be stimulated by both apoE and lipoprotein lipase (LPL). In the present study we investigated the effect of the isoform and the amount of apoE per particle, as well as the role of LPL on the binding of beta-VLDL to HSPG. Therefore, we isolated beta-VLDL from transgenic mice, expressing either APOE*2(Arg158-->Cys) or APOE*3-Leiden (E2-VLDL and E3Leiden-VLDL, respectively), as well as from apoE-deficient mice containing no apoE at all (Enull-VLDL). In the absence of LPL, the binding affinity and maximal binding capacity of all beta-VLDL samples for HSPG-coated microtiter plates was very low. Addition of LPL to this cell-free system resulted in a 12- to 55-fold increase in the binding affinity and a 7- to 15-fold increase in the maximal binding capacity (Bmax). In the presence of LPL, the association constant (Ka) tended to increase in the order Enull-VLDL<E2-VLDL<E3Leiden-VLDL, whereas Bmax increased in the reverse order: E3Leiden-VLDL approximately E2-VLDL<Enull-VLDL. Addition of LPL resulted in a marked stimulation of both Ka and Bmax for binding of beta-VLDL samples to J774 cells similar to that found for the binding to HSPG-LPL complexes. Our results indicate that both Ka and Bmax for binding of beta-VLDL to HSPG are increased more than 1 order of magnitude on addition of LPL. In addition, for the binding of beta-VLDL to HSPG-LPL complexes, the presence of apoE is not a prerequisite, but results in an increased binding affinity, depending on the apoE isoform used.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073967     DOI: 10.1161/01.atv.19.3.633

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

1.  Very-low-density lipoprotein binding to the apolipoprotein E receptor 2 is enhanced by lipoprotein lipase, and does not require apolipoprotein E.

Authors:  P J Tacken; F D Beer; L C Vark; L M Havekes; M H Hofker
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

Review 2.  Glycosaminoglycan remodeling during diabetes and the role of dietary factors in their modulation.

Authors:  Vemana Gowd; Abhignan Gurukar; Nandini D Chilkunda
Journal:  World J Diabetes       Date:  2016-02-25

Review 3.  Dissection of the complex role of apolipoprotein E in lipoprotein metabolism and atherosclerosis using mouse models.

Authors:  K W van Dijk; M H Hofker; L M Havekes
Journal:  Curr Atheroscler Rep       Date:  1999-09       Impact factor: 5.113

Review 4.  GPIHBP1 and Lipoprotein Lipase, Partners in Plasma Triglyceride Metabolism.

Authors:  Stephen G Young; Loren G Fong; Anne P Beigneux; Christopher M Allan; Cuiwen He; Haibo Jiang; Katsuyuki Nakajima; Muthuraman Meiyappan; Gabriel Birrane; Michael Ploug
Journal:  Cell Metab       Date:  2019-07-02       Impact factor: 27.287

5.  Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size.

Authors:  Daniël B van Schalkwijk; Albert A de Graaf; Ben van Ommen; Kees van Bochove; Patrick C N Rensen; Louis M Havekes; Niek C A van de Pas; Huub C J Hoefsloot; Jan van der Greef; Andreas P Freidig
Journal:  J Lipid Res       Date:  2009-06-10       Impact factor: 5.922

Review 6.  GPIHBP1 and Plasma Triglyceride Metabolism.

Authors:  Loren G Fong; Stephen G Young; Anne P Beigneux; André Bensadoun; Monika Oberer; Haibo Jiang; Michael Ploug
Journal:  Trends Endocrinol Metab       Date:  2016-05-14       Impact factor: 12.015

7.  Multiethnic Exome-Wide Association Study of Subclinical Atherosclerosis.

Authors:  Pradeep Natarajan; Joshua C Bis; Lawrence F Bielak; Amanda J Cox; Marcus Dörr; Mary F Feitosa; Nora Franceschini; Xiuqing Guo; Shih-Jen Hwang; Aaron Isaacs; Min A Jhun; Maryam Kavousi; Ruifang Li-Gao; Leo-Pekka Lyytikäinen; Riccardo E Marioni; Ulf Schminke; Nathan O Stitziel; Hayato Tada; Jessica van Setten; Albert V Smith; Dina Vojinovic; Lisa R Yanek; Jie Yao; Laura M Yerges-Armstrong; Najaf Amin; Usman Baber; Ingrid B Borecki; J Jeffrey Carr; Yii-Der Ida Chen; L Adrienne Cupples; Pim A de Jong; Harry de Koning; Bob D de Vos; Ayse Demirkan; Valentin Fuster; Oscar H Franco; Mark O Goodarzi; Tamara B Harris; Susan R Heckbert; Gerardo Heiss; Udo Hoffmann; Albert Hofman; Ivana Išgum; J Wouter Jukema; Mika Kähönen; Sharon L R Kardia; Brian G Kral; Lenore J Launer; Joe Massaro; Roxana Mehran; Braxton D Mitchell; Thomas H Mosley; Renée de Mutsert; Anne B Newman; Khanh-Dung Nguyen; Kari E North; Jeffrey R O'Connell; Matthijs Oudkerk; James S Pankow; Gina M Peloso; Wendy Post; Michael A Province; Laura M Raffield; Olli T Raitakari; Dermot F Reilly; Fernando Rivadeneira; Frits Rosendaal; Samantha Sartori; Kent D Taylor; Alexander Teumer; Stella Trompet; Stephen T Turner; Andre G Uitterlinden; Dhananjay Vaidya; Aad van der Lugt; Uwe Völker; Joanna M Wardlaw; Christina L Wassel; Stefan Weiss; Mary K Wojczynski; Diane M Becker; Lewis C Becker; Eric Boerwinkle; Donald W Bowden; Ian J Deary; Abbas Dehghan; Stephan B Felix; Vilmundur Gudnason; Terho Lehtimäki; Rasika Mathias; Dennis O Mook-Kanamori; Bruce M Psaty; Daniel J Rader; Jerome I Rotter; James G Wilson; Cornelia M van Duijn; Henry Völzke; Sekar Kathiresan; Patricia A Peyser; Christopher J O'Donnell
Journal:  Circ Cardiovasc Genet       Date:  2016-11-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.